about
Treatment options for nonalcoholic steatohepatitis - a safety evaluation.Lipids: Evergreen autofluorescent biomarkers for the liver functional profiling.Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine.Correlation between Traditional Chinese Medicine Constitution and Dyslipidemia: A Systematic Review and Meta-Analysis.Associations between fatty liver index and asymptomatic intracranial vertebrobasilar stenosis in Chinese population.Amentoflavone improves cardiovascular dysfunction and metabolic abnormalities in high fructose and fat diet-fed rats.Sleep apnea: An overlooked cause of lipotoxicity?Role of bisphenol A as environmental factor in the promotion of non-alcoholic fatty liver disease: in vitro and clinical study.Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis.Epigenetically mediated inhibition of S-adenosylhomocysteine hydrolase and the associated dysregulation of 1-carbon metabolism in nonalcoholic steatohepatitis and hepatocellular carcinoma.Mouse models for investigating the underlying mechanisms of nonalcoholic steatohepatitis-derived hepatocellular carcinoma.Protein interaction mapping interpretation of none alcoholic fatty liver disease model of rats after fat diet feeding.A Case of Concomitant Obstructive Sleep Apnea and Non-Alcoholic Steatohepatitis Treated With CPAP Therapy.Polymorphisms in the receptor for advanced glycation end-products (RAGE) gene and circulating RAGE levels as a susceptibility factor for non-alcoholic steatohepatitis (NASH).Supervised learning reveals circulating biomarker levels diagnostic of hepatocellular carcinoma in a clinically relevant model of non-alcoholic steatohepatitis; An OAD to NASH.Obesity and nonalcoholic fatty liver disease: current perspectivesNon-alcoholic fatty liver disease is a strong predictor of coronary artery calcification in metabolically healthy subjects: A cross-sectional, population-based study in middle-aged subjectsMetabolic effects of reduced growth hormone action in fatty liver disease
P2860
Q38713765-A2950008-4A15-44E5-B7C3-6EC005D90EAAQ41842349-42E365B9-7182-4907-9B77-45792C9C4BA0Q41921861-15D1CCF3-C69E-4139-AF7B-D4D871A6AB54Q47103489-C11E13F0-5635-43A3-A960-7F1E8D4A2E92Q47127406-67E86BD4-B254-4C43-875E-F44A7140F7FBQ47423975-98BB283A-5815-403A-BA06-93DEF84A9D43Q47671084-EC1B2281-DB76-49BC-949C-06042A2F7F8DQ48264487-BD1D825E-0D14-4151-B0A9-5BFC83FF6CA3Q49394966-3266252C-27D9-4CCD-8334-89BD9C08D66FQ50063376-0DA4EB12-51A9-4422-A0A3-4D917DA1D5F0Q54212012-5394F7AB-211C-4ED5-9CAD-905F75349813Q55034297-DEAE6DB6-EF39-42FF-AD66-F5C0DC31B2A1Q55284436-9F79C082-5A7E-4F10-A3A8-F12F48E84C4BQ55496728-3572393E-263F-4E7C-B772-FC730AF9412FQ55498607-363B843C-4842-40C9-A3B5-B13EB9214AA5Q57069715-A479D568-313F-4A02-BC15-83600D0DF7B5Q58722876-26AD31AE-ADEA-4789-ABDE-28134BE0BDC6Q58748917-DF8FF77B-4BCA-4923-84A6-3593E88AA57A
P2860
description
im Februar 2017 veröffentlichter wissenschaftlicher Artikel
@de
наукова стаття, опублікована в лютому 2017
@uk
name
Non-alcoholic fatty liver disease
@en
type
label
Non-alcoholic fatty liver disease
@en
prefLabel
Non-alcoholic fatty liver disease
@en
P2860
P1433
P1476
Non-alcoholic fatty liver disease
@en
P2093
Brent A Neuschwander-Tetri
P2860
P2888
P356
10.1186/S12916-017-0806-8
P407
P5008
P577
2017-02-28T00:00:00Z
P6179
1083941581